Trial Profile
Treatment initiation and switch in therapy from vitamin k antagoinst to dabigatran, rivaroxaban and apixaban as well as patients and physician characteristics associated with them
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Dec 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 03 Dec 2018 New trial record
- 14 Nov 2018 Results presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research